-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Since multiple sclerosis was first described more than 150 years ago, neurologists have struggled to predict the onset of progressive disease, a key milestone in determining clinical outcomes in relapsing-remitting multiple sclerosis (RRMS)
Therefore, brain and spinal cord atrophy in MRI volume changes may be a useful correlate of worsening disability and disease progression
To achieve this, they analyzed a subset of 54 patients (RR→SP) who converted to secondary progressive MS (SPMS) at 12 years of follow-up and compared them with similar baseline characteristics during this period But still RRMS (RR→RR) 54 matched individuals were compared
To do this, they used data from the entire study cohort and stratified all patients who maintained RRMS according to whether they remained stable or silently progressed over a 12-year observation period
They assessed all RRMS (n = 360) and SPMS (n = 47) patients and 80 matched controls
They found that compared with RRMS patients (-0.
Compared with RRMS patients (-0.
Each 1% increase in the rate of spinal cord atrophy was associated with a 69% (p < 0.
Asymptomatic progression and conversion to secondary progressive disease are primarily associated with cervical cord atrophy
Asymptomatic progression and conversion to secondary progressive disease primarily associated with cervical cord atrophy diagnosis
Spinal Cord Atrophy Predicts Progressive Disease in Relapsing Multiple Sclerosis.
Annals of Neurology
Leave a Comment here
